Immunome Inc. — Director's Dealing 2020

Oct 2, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-01

Reporting Person: Lefenfeld Michael (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (22222)		Direct
Warrant (right to buy)	$9.00	2023-06-02	Series A Convertible Preferred Stock (11111)		Direct
Stock Option (right to buy)	$0.36	2027-12-05	Common Stock (23933)		Direct
Stock Option (right to buy)	$2.40	2030-08-03	Common Stock (11111)		Direct

Footnotes

F1: Each share of Series A Preferred Convertible Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a one-for-one basis, has no expiration date and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.

F2: Immediately exercisable.

F3: Fully vested.

F4: One fourth (1/4th) of the shares subject to the option vest in equal monthly increment commencing September 4, 2020, subject to the
Reporting Person continuing to provide service through each such date.